The optimal non-invasive diagnostic imaging strategy for patients with suspected coronary artery disease (CAD) is widely debated. Computed Tomography Coronary Angiography (CTCA) and functional imaging are both guideline-recommended, although comparative effectiveness in patients with intermediate-high pre-test likelihood (PTL) is limited. Primary Hypothesis: We aim to establish if a personalised investigation strategy compared to CTCA first-line for allcomers, leads to improved patient outcomes. In a multi-centre, randomised trial, 4,000 patients newly referred for the investigation of suspected cardiac chest pain will be recruited and randomised (1:1) to either personalised care (first-line CTCA or functional imaging based on PTL) or CTCA first-line for allcomers. The primary endpoint is time to a composite of cardiovascular death, myocardial infarction, or unobstructed coronary arteries on invasive angiography. Follow up will occur at 6 and 12 months and then annually for up to four years for symptoms, quality of life, and guideline directed medical therapy usage. A cost-effectiveness analysis will be performed capturing impacts on health, measured in quality adjusted life years (QALYs) using the EQ-5D-5L, and costs (including investigations, procedures, procedural complications, medical treatment costs and any future hospital admissions) calculated. It will be possible for the whole trial pathway to be conducted remotely with the option to perform non-face-to-face consent, randomisation, and follow-up data collection including health-related quality of life. 20 UK sites ENROLMENT: First site opened April 2022 and recruitment is due to complete by July 2025, with an average recruitment of 135 patients a month to date. 3,407 patients recruited and randomised by the end of February 2025 CONCLUSION: This trial will address whether, in patients with suspected cardiac chest pain, a strategy of personalised investigation according to pre-test likelihood (PTL), compared to CTCA for allcomers, leads to improved patient outcomes, quality of life and cost-effectiveness.